Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled

Veru Inc. reported Q3 FY2026 results for the quarter ended June 30, 2026. Net loss was $7.0M, or $0.30 per share, with operating loss from continuing operations of $7.7M. Cash was $23.9M. The company said its Phase 2b PLATEAU trial is fully enrolled (239 patients) and interim analysis is expected in Q1 2027.

Original reporting
Published Aug 10, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled — source image
Decision brief

The 30-second read

$VERUNeutralMed
01

Why it matters

Traders can update expectations for the next major catalyst (Q1 2027 interim analysis) while reassessing funding risk given operating losses and cash on hand.

02

Market read

This is a combined financial and clinical execution update that refines the event timeline and burn-rate backdrop for a small-cap biotech.

03

What to watch

Cash balance ($23.9M) and rising R&D expense ($4.35M vs $3.02M) could increase dilution or financing risk before Q1 2027, offsetting the clinical timeline improvement.

Relevance 8/10Novelty 7/10Timing: today’s SEC-filed Q3 results plus PLATEAU full-enrollment milestone

Background

Veru is advancing enobosarm plus semaglutide in the PLATEAU Phase 2b trial and reported Q3 FY2026 financials for the quarter ended June 30, 2026.

Company-level read

Ticker impact

$VERUNeutralMedium confidence
Context

Veru reported Q3 FY2026 net loss of $7.0M and said its PLATEAU Phase 2b trial is fully enrolled, with interim analysis due in Q1 2027.

Expected impact

Likely supportive for risk appetite into the Q1 2027 interim, but near-term downside risk remains from continued operating losses and limited cash runway.

Evidence & confidence

Full enrollment reduces trial execution risk, but the article also highlights ongoing operating losses and modest cash balance, which can cap upside until interim efficacy/safety data.

Market effects

Adds incremental datapoint for obesity/weight-loss pharmacology pipeline competition, particularly GLP-1 combination strategies and lean-mass preservation claims.

No clear regional market linkage beyond US small-cap biotech sentiment.

Limited; trial enrollment and interim timing are company-specific and not a cross-market macro driver.

Counterpoint

Full enrollment does not guarantee positive interim results; the stock may still re-rate lower if interim efficacy or DXA lean-mass endpoints disappoint.

Key entities

  • Veru Inc.

    Reported Q3 FY2026 net loss and announced PLATEAU Phase 2b full enrollment, with interim analysis expected in Q1 2027.

  • Novo Nordisk

    Entered a clinical supply agreement with Veru for the PLATEAU trial (announced June 2026).

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib

$VERUMed

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

VERU INC. (VERU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress — Phase 2b PLATEAU cl